Journal article
Docetaxel and Irinotecan in Recurrent or Metastatic Head and Neck Cancer
Cancer, Vol.115(19), pp.4504-4513
10/01/2009
DOI: 10.1002/cncr.24528
PMCID: PMC2749918
PMID: 19634157
Abstract
BACKGROUND: Docetaxel and irinotecan have single-agent antitumor activity in squamous cell carcinoma of the head and neck (SCCHN). The authors sought to evaluate their combination in the treatment of patients with recurrent or metastatic SCCHN. METHODS: Eligibility criteria included recurrent or metastatic SCCHN with measurable disease, good performance status, and adequate laboratory parameters. Patients received docetaxel 35 mg/m(2) and irinotecan 60 mg/m(2), intravenously, on Days 1 and 8, every 21 days, until disease progression. The authors assessed UGT1A1 genotype, vascular endothelial growth factor (VEGF) in serum, and cyclooxygenase-2 and VEGF in baseline tumor tissue. RESULTS: Fifty-two patients were analyzable: 20 chemotherapy naive (Group A) and 32 previously treated with I chemotherapy regimen (Group B); 73% of patients had distant metastasis, and 60% were paclitaxel-exposed. In Group A, 3 (15%) patients achieved a partial response: in Group B, 1 (3%) patient achieved a partial response. Median progression-free survival (PFS) and overall survival were 3.3 and 8.2 months in Group A and 1.9 and 5.0 months in Group B, respectively. Common serious toxicities were diarrhea, fatigue, and anorexia. Patients with high serum VEGF had a median PFS of 2.8 months versus 1.7 months for patients with low VEGF (P =.085). CONCLUSIONS: Docetaxel and irinotecan had acceptable toxicities, but efficacy results in unselected patients with recurrent or metastatic SCCHN did not suggest an advantage over docetaxel alone or platinum-based regimens. Cancer 2009;115:4504-13. (C) 2009 American Cancer Society.
Details
- Title: Subtitle
- Docetaxel and Irinotecan in Recurrent or Metastatic Head and Neck Cancer
- Creators
- Athanassios Argiris - University of PittsburghAshley Buchanan - Cancer Research And BiostatisticsBruce Brockstein - Evanston Healthcare, Evanston, IL USAJill Kolesar - University of Wisconsin–MadisonMusie Ghebremichael - Dana-Farber Cancer InstituteMichael Pins - University of Illinois Urbana-ChampaignKristine Hahn - University of Wisconsin–MadisonRita Axelrod - Thomas Jefferson UniversityArlene Forastiere - Johns Hopkins University
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.115(19), pp.4504-4513
- Publisher
- Wiley
- DOI
- 10.1002/cncr.24528
- PMID
- 19634157
- PMCID
- PMC2749918
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Number of pages
- 10
- Grant note
- U24CA114737 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) CA-23,318; CA-21,115 / Eastern Oncology Cooperative Group
- Language
- English
- Date published
- 10/01/2009
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695799202771
Metrics
1 Record Views